While the Italian drug agency gives the green light to the third dose even under the age of 60, Indonesia is the first country in the world to authorize the emergency administration of the Novavax vaccine against Covid-19.
Developed by the US pharmaceutical company that received $ 1.75 billion from the US government to develop the recombinant protein vaccine. A technology that is already used in childhood vaccines against hepatitis B, meningococcus B, herpes zoster and papilloma virus.
The protocol provides for two doses of equal dosage 21 days apart. It is normally kept in refrigerators for up to six months. The two doses would provide protection against the coronavirus with an efficacy of 90.4%, even against variants of the virus.
“Novavax vaccine 90.4% effective”
by Valeria Pini
The fifth usable vaccine from next year by the European Union could be on the way after Pfizer-Biontech, Moderna, AstraZeneca and Johnson & Johnson. The response from the EMA, which started the permanent review of the vaccine as early as February and from the US FDA, is awaited, which should arrive by the end of the year.
The US biotechnology company confirms that it has requested authorization from the United Kingdom, the European Union, Canada, Australia, India and the Philippines. Production was entrusted to the Serum Institute of India, where AstraZeneca is also produced.
Novavax, a Covid vaccine different from all the ones we have
by Daniele Banfi
But how does it work?
The Novavax vaccine, known as NVX-CoV2373, is based on recombinant protein technology: molecules capable of assembling to form viral-like particles on the basis of which the body produces its immune response, triggering the formation of antibodies.
Covid, Novavax asks WHO for emergency authorization for the vaccine
Artificial spike proteins of the coronavirus (mimicking the structure of Sars-CoV-2) are created from a virus RNA sequence in the laboratory and initiated: a more traditional method, similar to the flu vaccine. The results of clinical trials on about 30,000 volunteers between the United States and Mexico explained that the efficacy is 90% comparable to that of mRna vaccines, but with fewer side effects. Some volunteers reported fatigue, headaches, and minor symptoms.
.